TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11908489

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP) started within 2 hours preoperatively (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intraaortic balloon pump (IABP) instituted intraoperatively (Group B)
Number of subjects: 60
Study: 9578871

Group type: EXPERIMENTAL
Intervention: BIPP impregnated ribbon gauze (Aurum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pope wicks (Xomed‐Teace)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silastic sheeting (Dow Corning)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tri‐adcortyl ointment (Squibb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7699846

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup (5 mg/kg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup (10 mg/kg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup
Number of subjects: 73
Study: 2529299

Group type: EXPERIMENTAL
Intervention: Unpleasant taste symptom in depressed patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Previous drug treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Prognosis, severity or type of depression
Number of subjects: 47

Group type: COMPARATOR
Intervention: Historical factors
Number of subjects: 47
Study: 686922

Group type: EXPERIMENTAL
Intervention: COAP (vincristine, prednisone, cytarabine 100 mg/sq m/day with cyclophosphamide)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: DOAP (vincristine, prednisone, cytarabine 100 mg/sq m/day with daunorubicin)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: OAP (vincristine, prednisone, cytarabine 200 mg/sq m/day)
Number of subjects: 274

Group type: COMPARATOR
Intervention: OAP (maintenance treatment)
Number of subjects: 274

Group type: COMPARATOR
Intervention: COAP (maintenance treatment)
Number of subjects: 274
Study: 31764727

Group type: EXPERIMENTAL
Intervention: Expedited scheduling for interval tubal ligation
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard scheduling for interval tubal ligation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Expedited scheduling
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard scheduling
Number of subjects: 126
Study: 28579168

Group type: EXPERIMENTAL
Intervention: Drug-coated stent (DCS)
Number of subjects: 1564

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1564
Study: 26590128

Group type: EXPERIMENTAL
Intervention: Niacin 100 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Niacin 500 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 23611248

Group type: EXPERIMENTAL
Intervention: Hard task difficulty
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Medium task difficulty
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Easy task difficulty
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3
Study: 21767340

Group type: EXPERIMENTAL
Intervention: Once daily detemir at 50, 65 or 80% of IV insulin requirements and aspart according to carbohydrate intake
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 82
Study: 19420391

Group type: EXPERIMENTAL
Intervention: Physical activities done outside of school time
Number of subjects: 1925
Study: 16896884

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg adjuvant to radiotherapy
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 1370
Study: 15103483

Group type: EXPERIMENTAL
Intervention: Extended clinical diagnostics with MRI and an expanded neuropsychological test battery (2000/2001)
Number of subjects: 343
Study: 11756857

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy for 4 to 5 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy for one year
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual performance measures (visual acuity, contrast sensitivity, threshold perimetry)
Number of subjects: 20
Study: 9008458

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Verapamil 480 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Verapamil (all doses combined)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9312340

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 90

Group type: COMPARATOR
Intervention: Double blind placebo
Number of subjects: 90
Study: 29860040

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial responders (PRRs) receiving ADA
Number of subjects: 0
Study: 30235984

Group type: EXPERIMENTAL
Intervention: EndoButton (EB) CL
Number of subjects: 102

Group type: COMPARATOR
Intervention: TightRope (TR) RT
Number of subjects: 102
Study: 26452650

Group type: EXPERIMENTAL
Intervention: Rapid advancement of enteral feeding
Number of subjects: 83

Group type: COMPARATOR
Intervention: Slow advancement of enteral feeding
Number of subjects: 83
Study: 24214881

Group type: EXPERIMENTAL
Intervention: Higher DBP concentrations (Q4)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Estimated free 25(OH)D (Q4 vs. Q1 of the 25(OH)D:DBP ratio)
Number of subjects: 262
Study: 21967019

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (conventionally treated)
Number of subjects: 24
Study: 21033613

Group type: EXPERIMENTAL
Intervention: Exercise group (pedaled 50 minutes on a bicycle ergometry at 60% of maximal effort once a week for 12 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 40
Study: 17711537

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial AUC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C(max)
Number of subjects: 0
Study: 16685862

Group type: EXPERIMENTAL
Intervention: Automatic segmentation method using a binary approximate kNN classifier followed by a three-class classifier for cartilage segmentation.
Number of subjects: 0
Study: 12724679

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Historic controls (62 patients)
Number of subjects: 21
Study: 10227333

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% plus beclomethasone dipropionate nasal spray
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray 0.03% alone
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Combined active therapy (ipratropium bromide plus beclomethasone)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Vehicle (matching placebo nasal spray)
Number of subjects: 533
Study: 8913958

Group type: EXPERIMENTAL
Intervention: Protein S deficiency
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Protein C deficiency
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antithrombin III deficiency
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasminogen deficiency
Number of subjects: 50

Group type: COMPARATOR
Intervention: Activated protein C ratio
Number of subjects: 50
Study: 2057268

Group type: EXPERIMENTAL
Intervention: Survanta (100 mg of phospholipid/kg)
Number of subjects: 798
Study: 6681934

Group type: COMPARATOR
Intervention: Adriamycin alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Adriamycin plus DDP
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patients with stable disease
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patients with increasing disease
Number of subjects: 78
Study: 30176281

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (100 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (starch, 100 mg/day)
Number of subjects: 30
Study: 30075678

Group type: EXPERIMENTAL
Intervention: Maximum Length Sequences (MLS)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Iterative Randomized Stimulation and Averaging (I‐RSA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Click level varied from 105 to 135 dB re: 1 μPa at rates from 100 to 1000 Hz
Number of subjects: 6
Study: 26459373

Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 465

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 465
Study: 25111109

Group type: EXPERIMENTAL
Intervention: Yoga exercise (60-minute sessions, twice per week for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 60
Study: 23176882

Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine (TIV) administered using a 2-step approach (0.1 mL followed by full dose if no reaction)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal saline (placebo) followed by full dose of TIV if no reaction
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Single dose of TIV
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Split dose of TIV
Number of subjects: 31
Study: 19796383

Group type: EXPERIMENTAL
Intervention: fibre-enriched milk drink
Number of subjects: 26

Group type: COMPARATOR
Intervention: lactose-free milk drink
Number of subjects: 26

Group type: COMPARATOR
Intervention: normal fat-free milk
Number of subjects: 26
Study: 17618805

Group type: EXPERIMENTAL
Intervention: Colonoscopy simulator training (treatment group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No additional training (control group)
Number of subjects: 24
Study: 15167948

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 100
Study: 11600822

Group type: EXPERIMENTAL
Intervention: Single dose Nevirapine (NVP)
Number of subjects: 111
Study: 9702286

Group type: EXPERIMENTAL
Intervention: Sodium valproate (divalproex sodium; Depakote)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 37
Study: 8045951

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (DEX)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2498025

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lidocaine response
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mexiletine vs Tocainide
Number of subjects: 30
Study: 31601716

Group type: EXPERIMENTAL
Intervention: Bilateral Hypoglossal Nerve Stimulation (HNS) using the Genio™ system
Number of subjects: 27
Study: 28854571

Group type: EXPERIMENTAL
Intervention: Web-based intervention providing personalized normative feedback and general information about alcohol
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Control group with access to a consumption diary only
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 1147
Study: 26184649

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1013
Study: 23294870

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ivermectin-metronidazole combined therapy
Number of subjects: 120
Study: 21318927

Group type: EXPERIMENTAL
Intervention: Face-to-face action planning intervention for diabetes patients
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Email-delivered intervention for active individuals
Number of subjects: 245
Study: 19380853

Group type: EXPERIMENTAL
Intervention: Peginterferon‐alpha2a, 360 microg/wk for 12 weeks, then 180 microg/wk to complete 72 weeks (group A)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Peginterferon‐alpha2a, 180 microg/wk for 48 weeks (group B)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Peginterferon‐alpha2a, 180 microg/wk for 72 weeks (group C)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Peginterferon‐alpha2a, 180 microg/wk for 48 weeks (group D)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Extended treatment duration (72 weeks vs 48 weeks)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Complete viral suppression at week 12 (groups A and B)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Complete viral suppression at week 12 (groups C and D)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Complete viral suppression at week 12
Number of subjects: 950
Study: 17082468

Group type: EXPERIMENTAL
Intervention: 3APS 50 mg BID for 3 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 3APS 100 mg BID for 3 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 3APS 150 mg BID for 3 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 3APS 150 mg BID for 17 months (open-label phase)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15383193

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg 3 times daily)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 11563808

Group type: EXPERIMENTAL
Intervention: Participants told they would be able to smoke during the study
Number of subjects: 92

Group type: COMPARATOR
Intervention: Participants told they would not be able to smoke
Number of subjects: 92

Group type: COMPARATOR
Intervention: Participants told they might be able to smoke
Number of subjects: 92
Study: 9762656

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) analysis including albumin CSF/PB ratio, MNC number, IgM, IgM index, C3, C4, NSE, S100, and lactate.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) analysis
Number of subjects: 33
Study: 8157579

Group type: EXPERIMENTAL
Intervention: Cefminox 1 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cefminox 2 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cefminox 1 g and 2 g
Number of subjects: 6
Study: 2969232

Group type: EXPERIMENTAL
Intervention: 3 g/d of oral thiamine hydrochloride for three months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Niacinamide placebo
Number of subjects: 11
Study: 1695

Group type: EXPERIMENTAL
Intervention: Timolol (Blocadren)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31135821

Group type: EXPERIMENTAL
Intervention: Early dialysis initiation (estimated GFR >10.5 mL/min/1.73 m2)
Number of subjects: 28468

Group type: COMPARATOR
Intervention: Acute inpatient dialysis initiations
Number of subjects: 28468

Group type: COMPARATOR
Intervention: Home dialysis as the initial modality
Number of subjects: 28468

Group type: COMPARATOR
Intervention: Arteriovenous access creation at hemodialysis initiation
Number of subjects: 28468
Study: 29429598

Group type: EXPERIMENTAL
Intervention: Button-hole technique (group I, 44 patients)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Lowest part of the anterior suture line technique (group II, 43 patients)
Number of subjects: 87
Study: 26792348

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Octreotide (in high risk patients)
Number of subjects: 306
Study: 24262719

Group type: EXPERIMENTAL
Intervention: Behavioral educational intervention
Number of subjects: 540

Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 540
Study: 21771247

Group type: EXPERIMENTAL
Intervention: Systems-based post-prostatectomy models
Number of subjects: 373

Group type: COMPARATOR
Intervention: D'Amico defined risk groups
Number of subjects: 373

Group type: COMPARATOR
Intervention: Kattan 10-year postoperative nomogram
Number of subjects: 373

Group type: COMPARATOR
Intervention: Surgical margin status
Number of subjects: 373

Group type: COMPARATOR
Intervention: Extracapsular extension
Number of subjects: 373
Study: 20452299

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 109

Group type: COMPARATOR
Intervention: Mute headphones (Control)
Number of subjects: 109
Study: 17563874

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 40
Study: 15784985

Group type: EXPERIMENTAL
Intervention: Bread containing resistant starch (6 g of resistant starch derived from tapioca per 2 slices)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (bread not containing resistant starch)
Number of subjects: 20
Study: 12403196

Group type: EXPERIMENTAL
Intervention: Priorix (MeMuRu)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M-M-R II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triviraten
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priorix + Varilrix (varicella vaccine)
Number of subjects: 0
Study: 10717600

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) treated fresh frozen plasma (FFP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nontreated autologous fresh frozen plasma (FFP)
Number of subjects: 12
Study: 7482430

Group type: EXPERIMENTAL
Intervention: Antithrombin III deficiency (< 70%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal Antithrombin III levels (> 70%)
Number of subjects: 40
Study: 2156706

Group type: EXPERIMENTAL
Intervention: 99mTc DMSA renal scanning
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous urography (IVU)
Number of subjects: 32
Study: 7023672

Group type: EXPERIMENTAL
Intervention: Prazosin alone (2 mg single dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg t.i.d.) for 3 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg t.i.d.) + Oxprenolol (40 mg t.i.d.) for 3 days
Number of subjects: 48
Study: 31256765

Group type: EXPERIMENTAL
Intervention: 25 h placement budget
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 40 h placement budget
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 55 h placement budget
Number of subjects: 116
Study: 30815684

Group type: EXPERIMENTAL
Intervention: High CP (19%) diet
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Medium CP (18%) diet
Number of subjects: 648

Group type: COMPARATOR
Intervention: Low CP (17%) diet
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: LMEMCP diet
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: MME diet
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: HCP diet
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: MCP diet
Number of subjects: 648
Study: 29116691

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO₂) at 2.2 bar for 90 minutes once a day, average number per patient: 4.7 sessions
Number of subjects: 49
Study: 28316746

Group type: EXPERIMENTAL
Intervention: Videotape education for home instruction
Number of subjects: 80
Study: 24795252

Group type: EXPERIMENTAL
Intervention: Sodium restriction (target sodium intake 50 mmol Na(+) per day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of sodium restriction and hydrochlorothiazide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Baseline treatment (no sodium restriction or hydrochlorothiazide)
Number of subjects: 45
Study: 22176941

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) in the morning (GXR AM)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) in the evening (GXR PM)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo plus psychostimulant
Number of subjects: 461
Study: 19749089

Group type: EXPERIMENTAL
Intervention: Strategy instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial, gain (cued), and maintenance conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures of WM capacity
Number of subjects: 0
Study: 16988993

Group type: EXPERIMENTAL
Intervention: Real exposure with neutral information (group expo)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sham exposure with positive information (group+)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sham exposure with negative information (group‐)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sham exposure with neutral information (group+/‐)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not exposed, no field-related information)
Number of subjects: 74
Study: 16039210

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 31

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 12015434

Group type: EXPERIMENTAL
Intervention: Low pre-exercise muscle glycogen (240 +/- 38 mmol kg(‐1) dry weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control pre-exercise muscle glycogen (398 +/- 52 mmol kg(‐1) dry weight)
Number of subjects: 6
Study: 9828867

Group type: EXPERIMENTAL
Intervention: Aromatherapy with essential oils (thyme, rosemary, lavender, and cedarwood) mixed with carrier oils (jojoba and grapeseed) applied daily.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Carrier oils (jojoba and grapeseed) applied daily (Control group).
Number of subjects: 86
Study: 7924285

Group type: EXPERIMENTAL
Intervention: Insulation wools (5 types: 2 rockwool, 3 glasswool)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulation wools with the smallest diameter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulation wools with the largest diameter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of 'shot' in rockwool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control test site (no insulation wools)
Number of subjects: 0
Study: 2668980

Group type: EXPERIMENTAL
Intervention: Rolipram
Number of subjects: 64

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 64
Study: 371644

Group type: EXPERIMENTAL
Intervention: Oral verapamil 480 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12